Focalin XR Dosing Guidelines
Start Focalin XR at 5 mg once daily in children (ages 6–17 years) and 10 mg once daily in adults, titrating weekly by 5 mg increments in children or 10 mg increments in adults, with maximum doses of 30 mg/day in pediatrics and 40 mg/day in adults. 1
Starting Doses by Age Group
- Children and adolescents (6–17 years): Begin with 5 mg once daily in the morning for patients not currently taking methylphenidate or dexmethylphenidate. 1
- Adults (≥18 years): Begin with 10 mg once daily in the morning for stimulant-naïve patients or those switching from non-methylphenidate stimulants. 1
- Patients already on immediate-release dexmethylphenidate (Focalin): Switch to the same total daily dose of Focalin XR. 1
- Patients currently on racemic methylphenidate: Convert to Focalin XR at half the total daily dose of racemic methylphenidate (because dexmethylphenidate is the active d-enantiomer). 1
Dose Titration Schedule
- Pediatric patients: Increase by 5 mg increments weekly until optimal symptom control is achieved or adverse effects emerge. 1
- Adult patients: Increase by 10 mg increments weekly following the same criteria. 1
- Timing of adjustments: Allow approximately one week at each dose level to ensure maximal benefit before escalating further. 1
- Monitoring during titration: Maintain weekly contact (office visit or telephone) for the first 2–4 weeks to assess response and tolerability. 2
Maximum Recommended Doses
- Children and adolescents: 30 mg/day is the maximum studied and recommended dose. 1
- Adults: 40 mg/day is the maximum studied and recommended dose. 1
- Doses above these limits have not been studied and are not recommended; if the maximum dose is ineffective, consider switching to an alternative medication or adding psychosocial interventions rather than exceeding the dose ceiling. 2, 1
Administration Instructions
- Timing: Administer once daily in the morning to minimize insomnia. 1
- Swallowing whole: Capsules may be swallowed intact. 1
- Sprinkling on applesauce: Capsules may be opened and the beads sprinkled over a spoonful of applesauce; consume the mixture immediately in its entirety and do not store for future use. 1
- Do not crush, chew, or divide: The capsules or their contents must remain intact to preserve the extended-release mechanism. 1
Baseline Assessment Before Initiation
- Cardiovascular screening: Obtain a history and physical examination to exclude essential hypertension and cardiac arrhythmias. 3
- Vital signs: Record baseline blood pressure, pulse, height, and weight. 2, 3
- Substance-use screening: Screen adolescents for substance-use symptoms to identify potential misuse risk. 2
Monitoring During Treatment
Titration Phase (First 2–4 Weeks)
- Weekly contact: Maintain telephone or office contact each week to assess efficacy and adverse effects. 2
- Rating scales: Obtain parent/teacher reports (children) or patient/significant-other reports (adults) before each dose increase to objectively measure response. 2
Maintenance Phase
- Monthly follow-up: Schedule appointments at least monthly until symptoms are stable. 2, 3
- Vital signs: Check blood pressure and pulse at least quarterly throughout treatment. 2, 3
- Growth monitoring: Weigh the patient at each visit to detect appetite suppression or weight loss; measure height periodically to monitor for growth suppression. 2
Weight-Based Dosing Limits in Children
- Children weighing <25 kg: Should generally not receive single doses exceeding 10 mg of dexmethylphenidate. 2
Common Pitfalls and Caveats
- Do not apply immediate-release dosing to Focalin XR: Starting doses of 2.5 mg dexmethylphenidate or 5 mg racemic methylphenidate pertain only to immediate-release formulations; Focalin XR starts at 5 mg (pediatric) or 10 mg (adult). 2, 3
- Dose-response relationship: In fixed-dose studies (10–30 mg/day in children; 20–40 mg/day in adults), all doses were effective versus placebo, but higher doses did not consistently provide greater average benefit and were associated with more adverse events and discontinuations. 1
- Adverse effects: The most common treatment-emergent adverse events include decreased appetite, insomnia, headache, and anxiety; these are typically mild to moderate and dose-related. 1
- Growth suppression: Consistently medicated children may experience temporary slowing in growth rate (approximately 2 cm less height and 2.7 kg less weight over 3 years); monitor growth parameters and consider drug holidays if growth is not as expected. 1
- Cardiovascular effects: Stimulants can increase blood pressure and heart rate; quarterly vital-sign checks are essential. 2, 3
- Seizure risk: Stimulants may lower the convulsive threshold in patients with a history of seizures or EEG abnormalities; discontinue if seizures occur. 1
- Visual disturbances: Accommodation difficulties and blurred vision have been reported; a dose-dependent increase in pupil diameter has been documented. 1, 4
Long-Term Use and Reevaluation
- Periodic reassessment: Periodically reevaluate the long-term usefulness of Focalin XR with periods off medication to assess functioning without pharmacotherapy; improvement may be sustained when the drug is temporarily or permanently discontinued. 1
- Duration of treatment: There is no body of controlled-trial evidence indicating how long patients with ADHD should be treated with Focalin XR, but pharmacological treatment may be needed for extended periods. 1